Study guide

11.2 Medications for Alcohol and Tobacco Use Disorders

National Certified Peer Recovery Support Specialist NCPRSS

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Introduction to the NCPRSS Examination

1.1 NCPRSS Exam Structure, Credentialing, and Eligibility 1.2 Study Framework, Exam Strategies, and Navigating Test Scenarios

2 Chapter 2: Foundations of the Peer Recovery Support Role

2.1 Defining the Peer Role: Lived Experience and Mutuality 2.2 Scope of Practice and Non-Clinical Role Boundaries 2.3 Differentiating the Peer Specialist from Clinical and Support Roles

3 Chapter 3: Peer Engagement, Advocacy, Intake, and Service Coordination

3.1 Relationship Building and Active Listening in Peer Work 3.2 Individual and Systems-Level Peer Advocacy 3.3 Community Resource Navigation and Connection 3.4 Screening and Intake: The Peer's Role at First Contact 3.5 Recognizing Indicators of Substance Use and Co-Occurring Disorders for Referral 3.6 Case Management and Service Coordination in Peer Practice

4 Chapter 4: Cultural Humility, Trauma-Informed Peer Support, and Self-Care

4.1 Cultural Humility and Diversity in Peer Support 4.2 Trauma-Informed Peer Principles and Safety 4.3 Peer Specialist Self-Care and Burnout Prevention 4.4 Reflective Supervision and Professional Growth

5 Chapter 5: Recovery Paradigms, Definitions, and Recovery Capital

5.1 Definitions, Principles, and Dimensions of Recovery 5.2 Recovery-Oriented Systems of Care (ROSC) 5.3 Recovery Capital Assessment and Growth

6 Chapter 6: Stages of Change and Motivational Interviewing in Peer Support

6.1 The Transtheoretical Model: Stages of Change 6.2 Motivational Interviewing Spirit and Principles 6.3 Core MI Communication Skills: OARS and Change Talk

7 Chapter 7: Diverse Pathways to Recovery

7.1 Mutual Aid and 12-Step Pathways 7.2 Secular, Cognitive, and Faith-Based Pathways 7.3 Harm Reduction and Medication-Assisted Pathways

8 Chapter 8: Person-Centered Recovery Planning and Crisis Support

8.1 Person-Centered Goal Setting and Strengths Assessment 8.2 Wellness Recovery Action Planning (WRAP) and Recovery Plans 8.3 De-escalation and Crisis Intervention in Peer Practice 8.4 Suicide Risk Recognition, Safety Planning, and 988 Lifeline

9 Chapter 9: Recovery Documentation, Communication, and Recurrence Support

9.1 Peer Documentation and Record Keeping Standards 9.2 Lapse, Relapse, and Recurrence Management 9.3 Family Systems and Peer Support for Loved Ones

10 Chapter 10: Addiction Neurobiology and Substance Classes

10.1 Neurobiology of Addiction and the Brain Reward System 10.2 Central Nervous System Depressants and Stimulants 10.3 Opioids, Cannabis, Hallucinogens, and Emerging Synthetics

11 Chapter 11: Medications, Overdose Response, and Infectious Disease Prevention

11.1 Medications for Opioid Use Disorder (MOUD) 11.2 Medications for Alcohol and Tobacco Use Disorders 11.3 Overdose Recognition, Naloxone Administration, and Post-Reversal Care 11.4 HIV, Viral Hepatitis, and Other Pathogens: Prevention, Testing, and Linkage

12 Chapter 12: Ethical Standards and Professional Boundaries

12.1 NAADAC/NCC AP Code of Ethics and Peer Standards 12.2 Dual Relationships, Power Dynamics, and Boundaries 12.3 Managing Conflicts of Interest and Personal Conduct

13 Chapter 13: Legal Regulations, Confidentiality, and Mandated Reporting

13.1 Federal Confidentiality Laws: 42 CFR Part 2 and HIPAA 13.2 Exceptions to Confidentiality and Permitted Disclosures 13.3 Mandated Reporting and Duty to Warn/Protect

14 Chapter 14: Peer Rights, Informed Consent, and Credential Maintenance

14.1 Peer Rights, Autonomy, and Informed Consent 14.2 NCPRSS Credential Maintenance, Renewal, and Professional Development

11.2 Medications for Alcohol and Tobacco Use Disorders

Key Takeaways Explain This Topic AI

Medications for Alcohol Use Disorder (MAUD) include three FDA-approved agents—Acamprosate, Disulfiram, and Naltrexone—alongside evidence-based off-label options such as Gabapentin and Topiramate.

Acamprosate (Campral) modulates NMDA glutamate and GABA neurotransmission to alleviate protracted post-acute withdrawal, is cleared entirely by the kidneys (making it safe in hepatic impairment but contraindicated in severe renal disease), and requires three-times-daily dosing.

Disulfiram (Antabuse) irreversibly blocks aldehyde dehydrogenase (ALDH), causing toxic acetaldehyde accumulation and severe physical distress upon alcohol consumption; it requires full cognitive consent, voluntary compliance, and vigilance against hidden environmental alcohols (mouthwashes, cooking extracts, topicals).

Naltrexone (oral Revia or monthly IM Vivitrol) blocks mu-opioid endorphin reward pathways, significantly reducing heavy drinking days and cravings, and forms the pharmacological basis of targeted extinction strategies such as the Sinclair Method.

Tobacco Use Disorder pharmacotherapy includes combination Nicotine Replacement Therapy (NRT), Bupropion (an NDRI that reduces cravings but lowers seizure threshold), and Varenicline (a partial nicotinic receptor agonist that blocks smoking reward and reduces withdrawal).

Last updated: October 2026

11.2 Medications for Alcohol and Tobacco Use Disorders

Note

Quick Answer: While opioid medications frequently receive significant public attention, Alcohol Use Disorder (AUD) and Tobacco Use Disorder represent two of the leading causes of preventable morbidity and mortality among individuals with substance use conditions. Medications for Alcohol Use Disorder (MAUD) include three FDA-approved agents— Acamprosate (restores glutamate/GABA balance; renally cleared), Disulfiram (aldehyde dehydrogenase inhibitor; aversion therapy), and Naltrexone (mu-opioid antagonist; blocks reward pathways)—as well as evidence-based off-label medications like Gabapentin and Topiramate . For Tobacco Use Disorder, first-line treatments encompass Nicotine Replacement Therapy (NRT) , Bupropion SR (NDRI; lowers seizure threshold), and Varenicline (partial nicotinic agonist). Certified Peer Recovery Support Specialists support peers by demystifying these medications, exploring readiness, supporting adherence, and mitigating side effects through open dialogue with medical providers.

Neurobiology of Alcohol Use Disorder and the Rationale for MAUD

Alcohol (ethanol) is a central nervous system depressant that exerts complex, diffuse effects across multiple neurotransmitter networks. Its primary neurochemical mechanisms involve:

GABAergic Potentiation: Alcohol binds to gamma-aminobutyric acid type A ( G A B A A GABA_A G A B A A ​ ) receptor complexes, enhancing the inhibitory effects of GABA. This produces sedation, muscle relaxation, anxiolysis, and cognitive slowing.

Glutamatergic Inhibition: Alcohol acts as an antagonist at N-methyl-D-aspartate (NMDA) glutamate receptors, suppressing the brain's primary excitatory neurotransmitter and impairing memory consolidation and motor coordination.

Dopaminergic and Endorphin Release: Alcohol stimulates the release of endogenous beta-endorphins, which bind to mu-opioid receptors and trigger dopamine release in the nucleus accumbens, reinforcing the desire to drink. ┌────────────────────────────────────────────────────────────────────────────────────────┐

  • │ ALCOHOL NEUROCHEMICAL BALANCE AND WITHDRAWAL │
  • ├────────────────────────────┬─────────────────────────────┬─────────────────────────────┤
  • │ Homeostatic Baseline │ Chronic Alcohol Exposure │ Abrupt Cessation │
  • │ • Balanced GABA inhibition │ • GABA receptors down-reg. │ • Profound GABA deficiency │
  • │ • Balanced NMDA excitation │ • NMDA receptors up-reg. │ • Massive Glutamate surge │
  • │ • Normal baseline tone │ • Tolerance developed │ • Seizures, DTs, Dysphoria │
  • └────────────────────────────┴─────────────────────────────┴─────────────────────────────┘
  • Chronic Adaptation and Protracted Withdrawal (PAWS)

With chronic heavy consumption, the central nervous system attempts to maintain homeostasis: it downregulates inhibitory GABA receptors and upregulates excitatory NMDA receptors . When alcohol is abruptly discontinued, the inhibitory brakes are removed while the hyperactive excitatory accelerator surges unchecked. This produces acute withdrawal: tremors, diaphoresis, tachycardia, hypertension, hallucinations, withdrawal seizures, and potentially fatal delirium tremens (DTs) (which requires acute medical detoxification with benzodiazepines).

Even after acute physical withdrawal resolves, neurochemical equilibrium does not instantly return. For weeks or months, individuals endure protracted withdrawal (Post-Acute Withdrawal Syndrome, or PAWS), characterized by hyper-glutamatergic tone, autonomic instability, insomnia, generalized anxiety, emotional blunting, and intense cravings. MAUD agents are specifically engineered to mitigate these chronic imbalances, significantly improving long-term recovery outcomes.

  • The Three FDA-Approved Medications for Alcohol Use Disorder (MAUD)
  • 1. Acamprosate (Campral)

Pharmacological Mechanism: Acamprosate is a synthetic compound chemically similar to the endogenous amino acid taurine and GABA. It acts as a modulator of NMDA receptors and normalizes hyperactive glutamatergic neurotransmission while restoring GABAergic tone. In simple terms, acamprosate acts as a neurochemical stabilizer, quieting the "brain chatter," chronic restlessness, and post-acute cravings experienced by individuals in early alcohol recovery.

Primary Indication: Acamprosate is indicated for the maintenance of abstinence in individuals with alcohol dependence who are already abstinent at treatment initiation. It is not effective for acute alcohol detoxification and does not treat acute withdrawal seizures or delirium tremens.

Organ Clearance & Hepatic Safety:

Acamprosate is excreted entirely unchanged by the kidneys via glomerular filtration.

It undergoes 0% hepatic metabolism and does not interact with the cytochrome P450 enzyme system.

Clinical Significance: Because many individuals with long-term severe alcohol use disorder present with alcoholic hepatitis, liver cirrhosis, elevated liver transaminases (ALT/AST), or co-occurring Hepatitis C, acamprosate is the safest MAUD agent in patients with hepatic impairment .

Contraindications and Cautions: Acamprosate is strictly contraindicated in patients with severe renal impairment (creatinine clearance ≤ 30 mL/min \le 30\text{ mL/min} ≤ 30 mL/min ). A dose reduction is required in moderate renal impairment ( 30 − 50 mL/min 30-50\text{ mL/min} 30 − 50 mL/min ).

Pill Burden and Adherence: The standard adult dosage is two 333 mg delayed-release tablets taken three times daily (TID), totaling 1,998 mg daily (6 large tablets per day). This significant pill burden is the primary cause of poor adherence; peer specialists frequently assist peers with pill organizers, phone reminders, and mealtime pairing.

2. Disulfiram (Antabuse)

Pharmacological Mechanism: Disulfiram operates as an irreversible inhibitor of the enzyme aldehyde dehydrogenase (ALDH) .

Under normal physiological conditions, ingested ethanol is metabolized in the liver by alcohol dehydrogenase (ADH) into acetaldehyde (a toxic, intermediate metabolite). Aldehyde dehydrogenase (ALDH) then rapidly converts acetaldehyde into harmless acetic acid (acetate) , which breaks down into water and carbon dioxide. Disulfiram blocks this second metabolic step: Alcohol Dehydrogenase (ADH) Aldehyde Dehydrogenase (ALDH)

  • [ ETHANOL ] ─────────────────────────────────► [ ACETALDEHYDE ] ─────────X─────────► [ ACETIC ACID ]
  • │ (BLOCKED BY
  • ▼ DISULFIRAM)
  • TOXIC ACCUMULATION (5-10x)

Severe Physical Distress:

  • Flushing & throbbing headache
  • Violent nausea & vomiting
  • Palpitations & tachycardia
  • Hypotension & chest tightness

The Disulfiram-Alcohol Reaction: If an individual ingests alcohol while taking disulfiram, blood acetaldehyde concentrations skyrocket to 5 to 10 times higher than normal levels. Within 10 to 30 minutes, the individual experiences severe, distressing physical symptoms:

Intense cutaneous facial flushing and bloodshot eyes.

Throbbing head and neck pain.

Violent nausea, copious vomiting, and abdominal cramping.

Tachycardia, palpitations, tachypnea, and diaphoresis.

Hypotension, dizziness, weakness, and chest constriction.

In severe cases (with large amounts of alcohol), the reaction can progress to cardiovascular collapse, cardiac arrhythmias, myocardial infarction, acute congestive heart failure, convulsions, or death.

Aversion Therapy and Cognitive Requirements: Disulfiram is a pure psychological deterrent (aversion therapy) . It has zero effect on neurological cravings , does not normalize neurotransmitters, and does not relieve protracted withdrawal. Its therapeutic efficacy relies entirely on the individual's conscious fear of becoming violently ill.

Important

Critical Exam and Practice Rules for Disulfiram:

Cognitive Consent: Disulfiram must never be administered covertly (e.g., family members slipping it into coffee). The individual must possess full cognitive capacity, complete comprehension of the reaction, and voluntary motivation to take it.

Enzyme Resynthesis Latency: Because disulfiram binds irreversibly to ALDH, sensitivity to alcohol persists for up to 10 to 14 days after the last dose , as the liver must synthesize entirely new enzymes.

Hidden Environmental Alcohols: Peers must be educated to inspect all household products. Ingesting or absorbing occult alcohol from cough syrups, elixirs, mouthwashes, vanilla or flavoring extracts, cooking wines, fondues, aftershave lotions, hand sanitizers, and topicals can precipitate a severe disulfiram reaction.

3. Naltrexone for AUD (Oral Revia and Injectable Vivitrol)

Pharmacological Mechanism: In the context of alcohol consumption, drinking stimulates the release of endogenous beta-endorphins. These endorphins bind to mu-opioid receptors, which removes an inhibitory GABAergic brake on dopamine neurons in the VTA, causing a rewarding dopamine spike in the nucleus accumbens.

Naltrexone is a mu-opioid receptor antagonist . By occupying mu-opioid receptors, naltrexone breaks this neurochemical chain: when the individual drinks alcohol, the endorphins are blocked from binding, preventing the surge of dopamine. Alcohol is rendered unrewarding—the individual may still experience motor impairment, but the euphoric "buzz" is eliminated.

Clinical Indications and Goals:

Naltrexone reduces overall alcohol cravings.

It significantly reduces the number of heavy drinking days and prevents a single "slip" or "lapse" from turning into a catastrophic, multi-week binge.

It is effective both for total abstinence and for harm-reduction goals (moderation or reduction of heavy drinking).

The Sinclair Method (Targeted Dosing / Pharmacological Extinction): While FDA-approved for daily dosing in abstinent individuals, many addiction clinicians utilize the Sinclair Method . Under this protocol, individuals take oral naltrexone (50 mg) strictly one hour before their first drink of the day . Over months, drinking without the opioid-mediated endorphin reward leads to "pharmacological extinction," progressively eroding the conditioned brain response to alcohol cues.

Formulations: Oral daily tablet (Revia, 50 mg) or monthly intramuscular injection (Vivitrol, 380 mg gluteal injection every 4 weeks). Vivitrol circumvents daily pill adherence challenges.

Caution

Contraindications and Organ Safety for Naltrexone in AUD:

Concurrent Opioids: Naltrexone is strictly contraindicated in any patient currently taking opioid pain medications, methadone, or buprenorphine. It will precipitate immediate, severe opioid withdrawal.

Hepatotoxicity: Naltrexone is metabolized by the liver. While therapeutic doses rarely cause liver failure, it carries a warning for dose-dependent hepatocellular injury. Baseline and periodic liver function tests (LFTs) are recommended; it is avoided in acute hepatitis or liver failure.

Comparative Summary: Medications for Alcohol and Tobacco Use Disorders

Medication Trade Name(s) Primary Mechanism Clinical Goal / Target Organ Clearance & Key Precautions Peer Support Considerations

Acamprosate Campral NMDA receptor modulator & GABA agonist; restores neurochemical balance Abstinence maintenance; mitigates post-acute withdrawal & craving 100% renal clearance; safe in hepatic disease; contraindicated in severe renal failure (CrCl < 30 mL/min) Adherence support for tid dosing (two 333 mg pills 3x/day); does not treat acute withdrawal

Disulfiram Antabuse Irreversible aldehyde dehydrogenase (ALDH) inhibitor Aversive deterrent to impulsive alcohol consumption Hepatic metabolism; contraindicated in severe cardiovascular disease, psychosis, or pregnancy Requires strict 12-hour pre-abstinence; education on hidden ethanol (mouthwashes, vinegars, topicals); not a craving reducer

Naltrexone ReVia (oral), Vivitrol (IM) Mu-opioid receptor antagonist; blocks euphoric dopamine release Reduction of heavy drinking days / craving reduction Hepatic metabolism; monitor liver function; strictly contraindicated in active opioid use (requires 7–14 day opioid washout) Must carry medical alert identification; opioids will be ineffective in trauma/surgery; peer reassurance that cutting back is valid

Nicotine Replacement Therapy (NRT) Nicorette, Nicoderm, etc. Low-dose nicotine agonist without combustible toxins Craving reduction and withdrawal attenuation Hepatic; caution in unstable coronary artery disease Can combine long-acting patch with short-acting gum/lozenge; normalizes tobacco recovery alongside other SUDs

Varenicline Chantix Alpha-4 beta-2 nicotinic acetylcholine receptor partial agonist Blunts smoking satisfaction and eases withdrawal cravings Primarily renal clearance; monitor for vivid dreams, mood changes Highest monotherapy cessation efficacy; peer validation during initial weeks of dose titration

Bupropion SR Zyban / Wellbutrin Norepinephrine-dopamine reuptake inhibitor (NDRI) Craving mitigation, mood support, attenuates weight gain Hepatic; strictly contraindicated in seizure disorders or active bulimia/anorexia Initiated 1–2 weeks before target quit date; beneficial for co-occurring depressive symptoms

Off-Label Pharmacotherapies for Alcohol Use Disorder

When FDA-approved medications are poorly tolerated, contraindicated, or ineffective, evidence-based addiction guidelines support several off-label medications:

Gabapentin (Neurontin):

Mechanism: Modulates voltage-gated calcium channels containing the α 2 δ \alpha_2\delta α 2 ​ δ subunit, indirectly increasing GABA neurotransmission.

Clinical Role: Excellent for treating early protracted alcohol withdrawal, targeting insomnia, generalized anxiety, restlessness, and cravings . It is cleared renally (safe in mild-to-moderate liver disease). However, peer specialists must note that gabapentin possesses potential for misuse and sedation, especially if combined with opioids or sedatives.

Topiramate (Topamax):

Mechanism: Antagonizes AMPA/kainate glutamate receptors and potentiates G A B A A GABA_A G A B A A ​ neurotransmission.

Clinical Role: Demonstrates robust efficacy in reducing heavy drinking days, alcohol cravings, and impulsivity. Notable adverse effects include cognitive slowing (often colloquially referred to by patients as "Dopamax"), word-finding difficulty, paresthesias (tingling in fingers/toes), taste perversion (carbonated beverages taste flat), and weight loss.

Pharmacotherapies for Tobacco / Nicotine Use Disorder

Tobacco use disorder remains the single greatest cause of preventable death, cancer, cardiovascular disease, and chronic lung disease globally. In behavioral health and addiction recovery settings, smoking prevalence ranges from 60% to over 80% , and individuals in long-term substance recovery are statistically more likely to die from tobacco-related illnesses than from their primary drug of choice. First-line pharmacotherapies include: ┌────────────────────────────────────────────────────────────────────────────────────────┐

  • │ TOBACCO / NICOTINE PHARMACOTHERAPY SPECTRUM │
  • ├──────────────────────────┬─────────────────────────────┬───────────────────────────────┤
  • │ 1. Nicotine Replacement │ 2. Bupropion SR (Zyban) │ 3. Varenicline (Chantix) │
  • │ • Delivers clean nicotine│ • Non-nicotine NDRI tablet │ • Partial α4β2 agonist │
  • │ • Transdermal patch │ • Reduces cravings & weight │ • Blocks smoking reward │
  • │ • Gum, lozenge, spray │ • LOWERS SEIZURE THRESHOLD │ • Most effective monotherapy │
  • │ • Combination NRT best │ • Contraindicated in eating │ • Take with water after meals │
  • │ (Patch + Gum/Lozenge) │ disorders & acute detox │ to prevent nausea │
  • └──────────────────────────┴─────────────────────────────┴───────────────────────────────┘
  • 1. Nicotine Replacement Therapy (NRT)

NRT provides "clean," controlled doses of nicotine to satisfy physical neurochemical dependence and alleviate acute withdrawal symptoms (irritability, anxiety, restlessness, weight gain, insomnia) without exposing the individual to the toxic carcinogens, carbon monoxide, and tar found in burning tobacco.

The Five Delivery Modalities:

Transdermal Patch (Long-Acting): Provides steady, basal nicotine delivery over 16 or 24 hours. Available in step-down doses (e.g., 21 mg, 14 mg, 7 mg). Side effects include local skin irritation and vivid dreams (mitigated by removing the 24-hour patch at bedtime).

Nicotine Gum (Short-Acting): 2 mg and 4 mg strengths. Requires a specific "chew and park" technique: chew briefly until a peppery taste or tingling sensation emerges, then park the gum between the cheek and gum tissue for buccal mucosal absorption. Swallowing saliva rapidly without parking causes gastrointestinal upset, nausea, and hiccups.

Nicotine Lozenge (Short-Acting): Dissolves slowly in the mouth over 20-30 minutes. Do not bite, chew, or swallow whole.

Important Behavioral Rule for Oral NRT: Avoid eating or drinking acidic beverages (coffee, soda, orange juice, tea) for at least 15 minutes before and during gum or lozenge use, as acid significantly reduces oral mucosal nicotine absorption.

Nasal Spray and Oral Inhaler (Prescription): Nasal spray delivers rapid nicotine spikes mimicking cigarette kinetics; oral inhaler replicates hand-to-mouth behavioral rituals.

Combination NRT (Gold Standard): Combining a long-acting formulation (transdermal patch for consistent baseline blood levels) with an acute, short-acting formulation (gum or lozenge for breakthrough cravings triggered by stress or environmental cues) produces dramatically higher long-term cessation rates than monotherapy.

2. Bupropion SR (Zyban / Wellbutrin SR)

Mechanism: Norepinephrine-Dopamine Reuptake Inhibitor (NDRI). By mildly boosting synaptic dopamine and noradrenaline levels, it mimics the neurochemical reward of nicotine and diminishes withdrawal symptoms.

Clinical Benefits: Non-nicotine oral tablet; assists in delaying or mitigating post-cessation weight gain; highly beneficial for individuals with co-occurring depressive symptoms.

Critical Contraindications: Bupropion significantly lowers the seizure threshold . It is strictly contraindicated in individuals with:

A current or past history of seizure disorders.

A current or prior diagnosis of anorexia nervosa or bulimia.

Individuals undergoing acute withdrawal from alcohol or sedatives (benzodiazepines).

3. Varenicline (Chantix)

Mechanism: A selective partial agonist at α 4 β 2 \alpha_4\beta_2 α 4 ​ β 2 ​ nicotinic acetylcholine receptors .

Dual Action: Its partial agonism stimulates moderate, steady dopamine release in the brain reward pathway, relieving nicotine withdrawal symptoms and cravings. Simultaneously, its high binding affinity blocks inhaled nicotine from attaching to the receptor; if the individual slips and smokes a cigarette, they receive zero pleasurable nicotine reinforcement.

Efficacy: Clinically proven to be the most effective single monotherapy for smoking cessation, consistently outperforming bupropion and single-agent NRT in head-to-head randomized trials.

Administration and Side Effects: Titrated over one week before the target quit date. The most common adverse effect is nausea (prevented by taking the tablet with a full meal and a large glass of water), along with insomnia and vivid dreams. Historical concerns regarding neuropsychiatric risks (depression, suicidal ideation) were evaluated in the large-scale EAGLES clinical trial, which found no significant increase in psychiatric events compared to placebo, leading the FDA to remove its former black-box warning.

The Peer Specialist Role in Alcohol and Tobacco Recovery

Peer specialists support individuals exploring MAUD and tobacco cessation through a compassionate, non-coercive lens:

Dismantling Recovery Hierarchies: Many traditional recovery spaces treat tobacco as an acceptable, benign habit while treating alcohol medications with skepticism. Peer specialists normalize that recovery encompasses whole-person health and that treating tobacco dependence increases, rather than decreases, the likelihood of sustained sobriety from alcohol and illicit drugs.

Exploring Readiness and Ambivalence: Using motivational interviewing to assess where the peer sits regarding alcohol reduction or smoking cessation without imposing unsolicited advice.

Supporting Adherence and Refill Schedules: Assisting peers in managing high-frequency regimens (such as Acamprosate's TID schedule) and anticipating medication refills before holidays or weekends.

Loading diagram... Mechanisms of Action for Alcohol and Tobacco Use Disorder Pharmacotherapies